Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Lercanidipine in hypertension Borghi CVasc Health Risk Manag 2005[]; 1 (3): 173-82Lercanidipine is a lipophilic, dihydropyridine calcium antagonist with a long receptor half-life. Its slow onset of action helps to avoid reflex tachycardia associated with other dihydropyridines (DHPs). It produces even and sustained blood pressure lowering with once-daily dosing. It has equivalent antihypertensive efficacy to many other agents and is effective as initial monotherapy or in combination. Efficacy has been demonstrated in elderly as well as younger patients and also in the presence of other risk factors. Lercanidipine is well tolerated with DHP-associated adverse effects occurring early in treatment. The incidence of pedal edema and subsequent withdrawals has been found to be lower with lercanidipine than with amlodipine or nifedipine gastrointestinal transport system. Preclinical and preliminary clinical findings suggest lercanidipine may have beneficial effects on atherosclerosis and left ventricular hypertrophy. The efficacy and tolerability profiles of lercanidipine make it a suitable choice for treating hypertension in a wide range of affected patients.|Adult[MESH]|Aged[MESH]|Aged, 80 and over[MESH]|Animals[MESH]|Antihypertensive Agents/adverse effects/pharmacokinetics/*therapeutic use[MESH]|Blood Pressure/drug effects[MESH]|Calcium Channel Blockers/adverse effects/pharmacokinetics/*therapeutic use[MESH]|Dihydropyridines/adverse effects/pharmacokinetics/*therapeutic use[MESH]|Humans[MESH]|Hypertension/*drug therapy/physiopathology[MESH]|Middle Aged[MESH]|Patient Compliance[MESH]|Practice Guidelines as Topic[MESH]|Severity of Illness Index[MESH]|Treatment Outcome[MESH] |
